MINNEAPOLIS, March 10,
2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that it has begun shipping the Leo™ System,
powered by Simple Western™ Technology. Leo expands upon existing
Simple Western platforms that offer automated protein size
resolution and antibody-based protein detection by dramatically
improving sample throughput and enhancing the reproducibility of
protein quantitation. Leo offers the throughput and precision of
standard ELISAs in a fully automated western blot assay, expanding
applications in bioanalytical workflows from discovery through
commercialization.
Leo enables the simultaneous processing of up to 100 samples in
a single 3-hour run, offering 4x the throughput of the Jess™ Simple
Western System and 5x faster turn-around-times than Sally Sue™ and
Peggy Sue™ Simple Western Systems. Leo also provides the
experimental size, precision and reproducibility necessary for
robust analytical grade protein quantitation for use in submissions
to regulatory agencies. Additionally, Leo features enhanced Compass
for Simple Western Software, with advanced analysis capabilities
and improvements to better support 21 CFR Part 11
Compliance.
"With Leo, scientists can achieve their development milestones
faster and more efficiently, completing studies with fewer runs,
operators and instruments," commented Will
Geist, President of Bio-Techne's Protein Sciences Segment.
"Leo will enable our customers to accelerate their cutting-edge
science and bring next generation therapies to market faster."
Early adopters have been thrilled with the power that Leo
brings, with beta testers praising the instrument's robust
performance, data quality, and wide range of applications,
including targeted protein degradation, clinical biomarker studies,
gene therapy potency assays, quality control and release assays,
recombinant protein expression and more.
Explore Leo's capabilities at bio-techne.com/leo.
Data on Leo's performance will be presented at an upcoming webinar.
Registration details can be found here.
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-techne-begins-shipping-leo---a-next-generation-high-throughput-simple-western-system-302395190.html
SOURCE Bio-Techne Corporation
